These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 9831792)

  • 21. Differential expression of collateral sensitivity or resistance to cisplatin in human bladder carcinoma cell lines pre-exposed in vitro to either X-irradiation or cisplatin.
    Bedford P; Shellard SA; Walker MC; Whelan RD; Masters JR; Hill BT
    Int J Cancer; 1987 Nov; 40(5):681-6. PubMed ID: 3679594
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytostatic sensitivity and MDR in bladder carcinoma cells: implications for tumor therapy.
    Schuldes H; Dolderer JH; Schoch C; Bickeböller R; Woodcock BG
    Int J Clin Pharmacol Ther; 2000 Apr; 38(4):204-8. PubMed ID: 10783830
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines.
    Hasegawa S; Abe T; Naito S; Kotoh S; Kumazawa J; Hipfner DR; Deeley RG; Cole SP; Kuwano M
    Br J Cancer; 1995 May; 71(5):907-13. PubMed ID: 7734314
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Establishment of cisplatin-resistant variants of human neuroblastoma cell lines, TGW and GOTO, and their drug cross-resistance profiles.
    Iwasaki I; Sugiyama H; Kanazawa S; Hemmi H
    Cancer Chemother Pharmacol; 2002 Jun; 49(6):438-44. PubMed ID: 12107547
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tunicamycin potentiates drug cytotoxicity and vincristine retention in multidrug resistant cell lines.
    Hiss D; Gabriels G; Jacobs P; Folb P
    Eur J Cancer; 1996 Nov; 32A(12):2164-72. PubMed ID: 9014761
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization and modulation of transitional cell carcinoma cell lines with acquired multidrug resistance.
    Yu DS; Chang SY; Ma CP
    Br J Urol; 1998 Feb; 81(2):234-40. PubMed ID: 9488065
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparison of rhodamine 123 accumulation and efflux in cells with P-glycoprotein-mediated and MRP-associated multidrug resistance phenotypes.
    Twentyman PR; Rhodes T; Rayner S
    Eur J Cancer; 1994; 30A(9):1360-9. PubMed ID: 7999426
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distinct mechanisms contribute to acquired cisplatin resistance of urothelial carcinoma cells.
    Höhn A; Krüger K; Skowron MA; Bormann S; Schumacher L; Schulz WA; Hoffmann MJ; Niegisch G; Fritz G
    Oncotarget; 2016 Jul; 7(27):41320-41335. PubMed ID: 27191498
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting urothelial carcinoma cells by combining cisplatin with a specific inhibitor of the autophagy-inducing class III PtdIns3K complex.
    Schlütermann D; Skowron MA; Berleth N; Böhler P; Deitersen J; Stuhldreier F; Wallot-Hieke N; Wu W; Peter C; Hoffmann MJ; Niegisch G; Stork B
    Urol Oncol; 2018 Apr; 36(4):160.e1-160.e13. PubMed ID: 29276062
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II).
    Mizutani Y; Yoshida O; Bonavida B
    J Urol; 1998 Aug; 160(2):561-70. PubMed ID: 9679929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Photodynamic activity of hypericin in human urinary bladder carcinoma cells.
    Kamuhabwa AR; Agostinis P; D'Hallewin MA; Kasran A; de Witte PA
    Anticancer Res; 2000; 20(4):2579-84. PubMed ID: 10953329
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transcribed ultraconserved region Uc.63+ promotes resistance to cisplatin through regulation of androgen receptor signaling in bladder cancer.
    Sekino Y; Sakamoto N; Ishikawa A; Honma R; Shigematsu Y; Hayashi T; Sentani K; Oue N; Teishima J; Matsubara A; Yasui W
    Oncol Rep; 2019 May; 41(5):3111-3118. PubMed ID: 30864720
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exogenous mutant p53 DNA enhanced cisplatin-induced apoptosis in TSGH-8301 human bladder cancer cells.
    Chang FL; Ling YF; Lai MD
    Anticancer Res; 2000; 20(1A):329-36. PubMed ID: 10769676
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancer.
    Chien M; Astumian M; Liebowitz D; Rinker-Schaeffer C; Stadler WM
    Cancer Chemother Pharmacol; 1999; 44(1):81-7. PubMed ID: 10367753
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human bladder cancer invasion model using rat bladder in vitro and its use to test mechanisms and therapeutic inhibitors of invasion.
    Fujiyama C; Jones A; Fuggle S; Bicknell R; Cranston D; Harris AL
    Br J Cancer; 2001 Feb; 84(4):558-64. PubMed ID: 11207054
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alterations in expression of the multidrug resistance-associated protein (MRP) gene in high-grade transitional cell carcinoma of the bladder.
    Clifford SC; Neal DE; Lunec J
    Br J Cancer; 1996 Mar; 73(5):659-66. PubMed ID: 8605104
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The clonogenic growth of cells derived from bladder barbotage in patients with transitional cell carcinoma of the bladder: a preliminary report.
    Niell HB; Soloway MS; Nissenkorn I
    J Urol; 1982 Apr; 127(4):668-70. PubMed ID: 7069828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rapid recovery of a functional MDR phenotype caused by MRP after a transient exposure to MDR drugs in a revertant human lung cancer cell line.
    Gonzalez Manzano R; Versanvoort C; Wright K; Twentyman PR
    Eur J Cancer; 1996 Nov; 32A(12):2136-41. PubMed ID: 9014757
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Accumulation of intracellular platinum is correlated with intrinsic cisplatin resistance in human bladder cancer cell lines.
    Koga H; Kotoh S; Nakashima M; Yokomizo A; Tanaka M; Naito S
    Int J Oncol; 2000 May; 16(5):1003-7. PubMed ID: 10762637
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of mechanisms responsible for resistance to idarubicin and daunorubicin in multidrug resistant LoVo cell lines.
    Toffoli G; Simone F; Gigante M; Boiocchi M
    Biochem Pharmacol; 1994 Nov; 48(10):1871-81. PubMed ID: 7986198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.